The development of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the pace of new treatments of human immunodeficiency virus (HIV) infections; nevertheless, recent developments in the treatment of CMV infections have resulted in improved human health and perhaps will encourage the development of new therapeutic approaches. First, the deployment of ganciclovir and valganciclovir for both the prevention and treatment of CMV infections and disease in transplant recipients has been further improved with the licensure of the efficacious and less toxic letermovir. Regardless, late-onset CMV disease, specifically pneumonia, remains problematic. Second, the treatment of congenital CMV infections with valganciclovir has beneficially improved both hearing and neurologic outcomes, both fundamental advances for these children. In these pediatric studies, viral load was decreased but not eliminated. Thus, an important lesson learned from studies in both populations is the need for new antiviral agents and the necessity for combination therapies as has been shown to be beneficial in the treatment of HIV infections, among others. The development of monoclonal antibodies, sirtuins, and cyclopropovir may provide new treatment options.

中文翻译：

---

巨细胞病毒感染治疗方法的开发进展。

巨细胞病毒（CMV）感染疗法的开发虽然在不断发展，但与人类免疫缺陷病毒（HIV）感染的新疗法步伐不符。但是，CMV感染治疗的最新进展已改善了人类健康，也许会鼓励开发新的治疗方法。首先，随着有效和毒性较小的letermovir的获得许可，更昔洛韦和缬更昔洛韦在移植受者中预防和治疗CMV感染和疾病的部署得到了进一步改善。无论如何，迟发的CMV疾病，特别是肺炎，仍然是有问题的。其次，用缬更昔洛韦治疗先天性巨细胞病毒感染可有效改善听觉和神经功能，这些孩子的两个根本进步。在这些儿科研究中，病毒载量减少但并未消除。因此，从这两个人群的研究中吸取的重要教训是对新抗病毒药物的需求以及联合疗法的必要性，这已被证明对治疗HIV感染特别有益。单克隆抗体，sirtuins和cyclopropovir的开发可能会提供新的治疗选择。